Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies

 
• By Joseph Haas

Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Merck & Co. hopes CAR-NK therapies may succeed where CAR-Ts have failed in solid tumors

More from Deals

More from Business